Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, Grünig E, Jansa P, Klinger JR, Langleben D, McLaughlin VV, Meyer GMB, Ota-Arakaki J, Peacock AJ, Pulido T, Rosenkranz S, Vizza CD, Vonk-Noordegraaf A, White RJ, Chang M, Kleinjung F, Meier C, Paraschin K, Ghofrani HA, Simonneau G; REPLACE investigators. Hoeper MM, et al. Among authors: mclaughlin vv. Lancet Respir Med. 2021 Jun;9(6):573-584. doi: 10.1016/S2213-2600(20)30532-4. Epub 2021 Mar 24. Lancet Respir Med. 2021. PMID: 33773120 Clinical Trial.
Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension.
Hoeper MM, Galié N, Murali S, Olschewski H, Rubenfire M, Robbins IM, Farber HW, McLaughlin V, Shapiro S, Pepke-Zaba J, Winkler J, Ewert R, Opitz C, Westerkamp V, Vachiéry JL, Torbicki A, Behr J, Barst RJ. Hoeper MM, et al. Am J Respir Crit Care Med. 2002 Feb 1;165(3):341-4. doi: 10.1164/ajrccm.165.3.200109-0130c. Am J Respir Crit Care Med. 2002. PMID: 11818318
Sitaxsentan therapy for pulmonary arterial hypertension.
Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR; STRIDE-1 Study Group. Barst RJ, et al. Am J Respir Crit Care Med. 2004 Feb 15;169(4):441-7. doi: 10.1164/rccm.200307-957OC. Epub 2003 Nov 20. Am J Respir Crit Care Med. 2004. PMID: 14630619 Clinical Trial.
Prostanoid therapy for pulmonary arterial hypertension.
Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O, Barst RJ. Badesch DB, et al. Among authors: mclaughlin vv. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):56S-61S. doi: 10.1016/j.jacc.2004.02.036. J Am Coll Cardiol. 2004. PMID: 15194179 Free article. Review.
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin LJ, Simonneau G. Sitbon O, et al. Among authors: mclaughlin vv. Thorax. 2005 Dec;60(12):1025-30. doi: 10.1136/thx.2005.040618. Epub 2005 Jul 29. Thorax. 2005. PMID: 16055621 Free PMC article.
193 results